abstract |
The present invention relates to compounds of formula I wherein y is n or c-r '; g is a 5- or 6-membered aromatic or heteroaromatic ring containing 0, 1, 2 or 3 heteroatoms, selected from the group consisting of phenyl, pyridinyl, n-imidazolyl, pyrazinyl, pyrimidinyl, thiophenyl, thiazolyl and pyrazolyl or thiadiazolyl, which are optionally substituted with 1, 2 or 3 substituents, selected from the group consisting of halogen, lower alkyl, lower alkoxy, halogen substituted lower alkoxy or nrr '; r and r 'are each independently hydrogen or lower alkyl or together with the n atom to which they are attached form a five or six membered saturated heterocyclic group which may contain an atom additional oxygen or nh or n- (lower alkyl) group; r1 represents a hydrogen atom, a halogen atom or a lower alkyl group substituted with halogen; R1 'is a hydrogen atom, a halogen atom or a lower alkyl group substituted by halogen; r2 represents a hydrogen atom or a lower alkyl, lower alkoxyalkyl, cycloalkyl or heterocycloalkyl group; or r2 may together with the nearest carbon atom in a group g form a group (ia), where a represents -ch2-, -ch2ch2 or -c (ch3) 2-; r3 is a phenyl or pyridinyl group, the n atom in the pyridinyl group may be in different positions; or on a pharmaceutically acceptable salt or acid addition salt thereof, on a racemic mixture thereof or on its corresponding enantiomer and / or optical isomer and / or stereoisomer. It has been unexpectedly found that the compounds of general formula I are positive allosteric modulators (pam) of the metabotropic glutamate receptor 4 (mglu4), useful for the treatment of Parkinson's disease, anxiety, vomiting, obsessive-compulsive disorder, autism, neuroprotection, and treatment for cancer, depression, and type 2 diabetes. |